Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INCA033989 PK and Safety Study in Healthy Adults
NCT07448155Phase 1Active, not recruiting
- Sponsor
- Incyte
- Start
- Mar 2026
- Primary completion
- Nov 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of inca033989 (7 cohorts), sponsored by Incyte. Primary endpoints: Maximum Observed Plasma Concentration at 12 weeks, Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Quantifiable Concentration at 12 weeks and 2 more. Started Mar 2026; status: active, not recruiting.
02
Drugs
inca033989
Beyond the preview
Go deeper on NCT07448155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07448155.